BioCryst Pharmaceuticals BCRX Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's effective income tax rate reconciliation nondeductible expense share based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's effective income tax rate reconciliation nondeductible expense share based compensation cost?
- BioCryst Pharmaceuticals (BCRX) reported effective income tax rate reconciliation nondeductible expense share based compensation cost of 2% in Q4 2025.
- What does effective income tax rate reconciliation nondeductible expense share based compensation cost mean?
- Measures the impact of non-deductible share-based compensation expenses on the company's effective tax rate. Because certain stock-based awards may not be tax-deductible, this metric highlights the tax inefficiency created by equity compensation programs. It provides insight into the tax consequences of the company's human capital incentive strategy.